Search results for "AGENTS"

showing 10 items of 7330 documents

A conservative treatment for chronic obstructive sialoadenitis by intraductal instillation of mucolytic, steroids and antibiotic solution

2021

Abstract Purposes Reporting our experience in treating chronic obstructive sialadenitis with a protocol consisting of sialoendoscopy and intraductal instillation of antibiotics, steroids and n-acetyl-cysteine (NAC) solution. Methods Prospective study of patients with chronic obstructive sialadenitis with no apparent lithiasic obstructions, with recurrent non-lithiasic sialoadenitis and patients with lithiasic sialoadenitis not solved with sialoendoscopy. In all cases, a sialoendoscopy was performed. All the patients affected by lithiasic sialoadenitis where the chronic inflammation was resolved with sialoendoscopy were excluded from the study. The mid-term follow-up was performed at 12 mont…

medicine.medical_specialtymedicine.drug_classAntibioticsConservative TreatmentIntraductal instillationSialadenitisChronic obstructive sialadenitismedicineHumansProspective StudiesSialoendoscopyProspective cohort studyExpectorantsbusiness.industryEndoscopyGeneral Medicinemedicine.diseaseSialadenitisSurgeryMiscellaneousAnti-Bacterial AgentsConservative treatmentOtorhinolaryngologyOtorhinolaryngologySialoendoscopyBetamethasoneSteroidsNeurosurgerybusinessmedicine.drug
researchProduct

[Antimicrobically coated venous catheters--must? Contra].

2002

medicine.medical_specialtymedicine.drug_classAntibioticsMEDLINEDrug resistanceCritical Care and Intensive Care MedicineCatheterizationAnti-Infective AgentsmedicineHumansIntensive care medicineVeinAntibacterial agentbusiness.industryDrug Resistance MicrobialGeneral MedicineBacterial InfectionsSurgeryCatheterAnesthesiology and Pain Medicinemedicine.anatomical_structureEmergency MedicineAnti-Infective Agents LocalAnti-Infective AgentsbusinessComplicationAnasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS
researchProduct

Treatment of cervicofacial actinomycosis: a report of 19 cases and review of literature

2013

Objectives: Actinomycosis is a chronic suppurative granulomatous infection caused by the Actinomyces genus. Orocervicofacial actinomycosis is the most common form of the disease, seen in up to 55% of cases. All forms of actinomycosis are treated with high doses of intravenous penicillin G over two to six weeks, followed by oral penicillin V. Large studies on cervicofacial actinomycosis are lacking. Therefore proper guidelines for treatment and treatment duration are difficult to establish. The aim of this study is to establish effective treatment and treatment duration for orocervicofacial actinomycosis. Study design: A Pubmed and Embase search was performed with the focus on treatment and …

medicine.medical_specialtymedicine.drug_classAntibioticsOdontologíaActinomycosis CervicofacialSDG 3 - Good Health and Well-beingClavulanic acidmedicineHumansCombined Modality TherapyGeneral DentistryRetrospective StudiesOral Medicine and Pathologybusiness.industryRetrospective cohort studyAmoxicillin:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCombined Modality TherapyCiencias de la saludDermatologyAnti-Bacterial AgentsSurgeryPenicillinOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASEtiology/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingResearch-ArticleSurgeryActinomycosisbusinessmedicine.drugMedicina Oral, Patologia Oral y Cirugia Bucal
researchProduct

Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs on the Small and Large Bowel

1999

Nonsteroidal anti-inflammatory drugs (NSAID) account for a large part of prescriptions and self-administered medication worldwide. The adverse effects on the upper gastrointestinal tract are well documented. However, in an increasing number of publications adverse effects in the small and large intestine distal to the duodenum are being reported. This paper provides an updated review of current as well as earlier literature on the pathogenesis of such adverse effects and the potential damage to the small and large bowel caused by NSAID. In addition, suggestions for an appropriate diagnostic workup of NSAID damage are discussed.

medicine.medical_specialtymedicine.drug_classBiopsydigestive systemGastroenterologyEndoscopy GastrointestinalAnti-inflammatorychemistry.chemical_compoundInternal medicineIntestine SmallmedicineHumansUpper gastrointestinalLarge intestineIntestine LargeIntestinal MucosaAdverse effectUlcerNonsteroidalbusiness.industryAnti-Inflammatory Agents Non-SteroidalGastroenterologydigestive system diseasesSmall intestineIntestinal Diseasesmedicine.anatomical_structurechemistryDuodenumbusinessComplicationEndoscopy
researchProduct

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension deliver…

2018

COPD causes considerable health and economic burden worldwide, with incidence of the disease expected to continue to rise. Inhaled bronchodilators, such as long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs), are central to the maintenance treatment of patients with COPD. Clinical studies have demonstrated that combined LAMA + LABA therapies improve efficacy while retaining a safety profile similar to LAMA or LABA alone. This has led to the development of several LAMA/LABA fixed-dose combination (FDC) therapies, which provide patients with the convenience of two active compounds in a single inhaler. GFF MDI (Bevespi Aerosphere®) is an FDC of glycopyrrolate/formote…

medicine.medical_specialtymedicine.drug_classDrug CompoundingFixed-dose combinationMuscarinic AntagonistsPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineFormoterol FumarateBronchodilatorAdministration InhalationmedicineHumans030212 general & internal medicineIntensive care medicineAdrenergic beta-2 Receptor AgonistsGlycopyrrolateCOPDbiologybusiness.industryInhalerGeneral MedicineLamamedicine.diseasebiology.organism_classificationGlycopyrrolateMetered-dose inhalerBronchodilator AgentsDrug CombinationsTreatment Outcome030228 respiratory systemFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

The Clinical Relevance of LDL Size and Subclasses Modulation in Patients with Type-2 Diabetes

2007

increasing evidence suggest that the "quality" rather than only the "quantity" of low density lipoproteins (LDL) exerts a great influence on the cardiovascular risk. Hypertriglyceridemia, low HDL-cholesterol and increased levels of small dense LDL characterise diabetic dyslipidemia. in subjects with type-2 diabetes LDL size seems also to represent a good marker of clinical apparent and non-apparent atherosclerosis. Recently, the Coordinating Committee of the National Cholesterol Education Program stated that high-risk patients may benefit of stronger therapeutical approaches, a category of subjects that include those with type-2 diabetes. Screening for the presence of small, dense LDL may p…

medicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismAtorvastatinPharmacologyEndocrinologyEzetimibeInternal medicineInternal MedicineHumansMedicineGemfibrozilCholesterol absorption inhibitorNational Cholesterol Education ProgramHypolipidemic Agentssmall dense LDL subclasses fibrates statins ezetimibe diabetes high-riskFenofibrateBezafibratebusiness.industryHypertriglyceridemiaGeneral Medicinemedicine.diseaseLipoproteins LDLMolecular WeightEndocrinologyDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)businessmedicine.drugExperimental and Clinical Endocrinology & Diabetes
researchProduct

Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.

2018

OBJECTIVE To determine the current state of knowledge and provide evidence-based recommendations that could be valid for all specialists taking care of female pattern hair loss (FPHL), a common form of hair loss in women that is characterized by the reduction of hair density in the central area of the scalp, whereas the frontal hairline is generally well conserved. PARTICIPANTS An expert task force appointed by the Androgen Excess and PCOS Society, which included specialists from dermatology, endocrinology, and reproductive endocrinology. DESIGN Levels of evidence were assessed and graded from A to D. Peer-reviewed studies evaluating FPHL published through December 2017 were reviewed. Crite…

medicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismVasodilator AgentsClinical BiochemistryReproductive EndocrinologySpironolactoneAndrogen ExcessBiochemistry030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineEndocrinology5-alpha Reductase InhibitorsInternal medicinemedicineVitamin D and neurologyHumansLow-Level Light TherapyMineralocorticoid Receptor Antagonists030219 obstetrics & reproductive medicineScalpintegumentary systembusiness.industryPlatelet-Rich PlasmaBiochemistry (medical)HyperandrogenismAlopeciaAndrogen Antagonistsmedicine.diseaseAndrogenDermatologymedicine.anatomical_structureEndocrinologyHair lossMinoxidilScalpMinoxidilFemalebusinessHyperandrogenismmedicine.drugPolycystic Ovary SyndromeThe Journal of clinical endocrinology and metabolism
researchProduct

Steroid and vasoactive treatment for acute deafness after attempted hearing preservation acoustic neuroma surgery.

2004

<i>Objective:</i> To investigate whether intravenous steroid and vasoactive therapy in the acute postoperative period improves hearing outcome in patients who develop acute deafness after attempted hearing preservation surgery for acoustic neuroma (AN) through a retrosigmoid or a middle cranial fossa approach. <i>Study Design and Setting:</i> Retrospective controlled study in a tertiary care center. Thirty-six patients who had developed acute deafness after hearing preservation surgery for treatment of an AN were reviewed. Preoperative AAOHNS hearing class was A in 2, B in 2 and D in 32 patients. Twenty-seven patients were treated with prednisolone, hydroxyethyl star…

medicine.medical_specialtymedicine.drug_classHearing lossmedicine.medical_treatmentPrednisoloneVasodilator AgentsAnti-Inflammatory AgentsAcoustic neuromaDeafnessHydroxyethyl Starch DerivativesPostoperative ComplicationsAcoustic neuroma surgeryVasoactiveotorhinolaryngologic diseasesmedicineEvoked Potentials Auditory Brain StemHumansIn patientPentoxifyllineRetrospective StudiesSalvage TherapyHearing preservationChemotherapybusiness.industryNeuroma Acousticmedicine.diseaseSurgeryOtorhinolaryngologyAnesthesiaAcute DiseaseInjections IntravenousCorticosteroidDrug Therapy Combinationmedicine.symptombusinessORL; journal for oto-rhino-laryngology and its related specialties
researchProduct

From structural biochemistry to expression profiling: Neuroprotective activities of estrogen

2005

Abstract Estrogens are neuromodulatory and neuroprotective hormones. Chemically, estrogens are steroid compounds and unfold most of their activities through the activation of nuclear receptors that bind to specific target genes and control their transcription. Two subtypes of estrogen receptors are known (estrogen receptor α and estrogen receptor β) and they are expressed throughout the body including the CNS and in particular the brain. We employed large scale DNA-chip-analysis to display the gene expression pattern differentially regulated by both estrogen receptor subtypes in human neuronal cells. We identified different gene families regulated by estrogen receptors that complement the k…

medicine.medical_specialtymedicine.drug_classModels NeurologicalEstrogen receptorBiologyNeuroprotectionAntioxidantsCell Line TumorInternal medicinemedicineHumansEstrogen receptor betaPELP-1EstradiolGene Expression ProfilingGeneral NeuroscienceBrainEstrogensCell biologyGene expression profilingNeuroprotective AgentsEndocrinologyReceptors EstrogenNuclear receptorEstrogenFemaleNervous System Diseaseshormones hormone substitutes and hormone antagonistsHormoneNeuroscience
researchProduct

The role of fibrate treatment in dyslipidemia: an overview.

2012

Dyslipidemia, and especially atherogenic dyslipidemia, a combination of small low-density lipoproteins cholesterol (LDL-C), decreased high-density lipoprotein cholesterol (HDL-C) and increased triglyceride (TG) concentrations, represents a major cardiovascular (CV) risk factor. Nuclear receptor peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid metabolism; PPAR ligands are used to treat dyslipidemias. Fibrates have a major impact on TG metabolism as well as on modulating LDL size and subclasses. Fibrates target atherogenic dyslipidemia by increasing plasma HDL-C concentrations and decreasing small dense LDL (sdLDL) particles and TGs, thus contributin…

medicine.medical_specialtymedicine.drug_classPeroxisome proliferator-activated receptorAdipokineFibratechemistry.chemical_compoundInternal medicineDrug DiscoverymedicineAnimalsHumansTriglyceridesDyslipidemiasHypolipidemic AgentsPharmacologychemistry.chemical_classificationTriglycerideCholesterolbusiness.industryFibric Acidsnutritional and metabolic diseasesLipid metabolismCholesterol LDLmedicine.diseaseFibrates dyslipidemia cardiovascular risk diabetes.EndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Metabolic syndromebusinessDyslipidemiaCurrent pharmaceutical design
researchProduct